

References

1. **Adeghate E, Schattner P, Dunn E.(2006)** : An update on the etiology and epidemiology of diabetes mellitus. Ann N Y Acad Sci ;1084:1–29.
2. **Alberti KG & Zimmet PZ (1998)** : Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine, 15: 539-553.
3. **Al-Lawati JA., Al Riyami AM, Mohammed AJ, Jousilahti P., (2002):** Increasing prevalence of diabetes mellitus in Oman. Diabetic Medicine,19(11):954–957.
4. **Alm A., (1992):** Ocular circulation. In: Hart WM, ed. Adler's physiology of the eye, St Louis: Mosby–Year Book; 1992:198-227
5. **Alm A & Bill A., (1973):** Ocular and optic nerve blood flow at normal and increased intraocular pressures in monkeys (*Macaca irus*): a study with radioactively labelled microspheres including flow determinations in brain and some other tissues. Exp Eye Res ; 15:15-29.
6. **Allt G & Lawrenson JG, (2001):** Pericytes: cell biology and pathology. Cells Tissues Organs; 169:1–11.

7. **Amos AF, McCarty DJ, Zimmet P. (1997)** : The rising global burden of diabetes and its complications: estimates and projections to the year 2010. *Diabetic Medicine* ; 14: S1-85.
8. **Arden GB & Wolf JE., (2000):** The human electro-oculogram: interaction of light and alcohol. *Invest Ophthalmol Vis Sci* ; 41:2722-2729
9. **Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al., (2007):** Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan American Collaborative Retina Study Group at 6-month follow-up. *Ophthalmology* ;114:743–750
10. **Aroca PR, Salvat M, Fernandez J, Mendez I. (2004):** Risk factors for diffuse and focal macular edema. *J Diabetes Complications*.18(4):211—5
11. **Barber AJ & Antonetti DA, (2003):** Mapping the blood vessels with paracellular permeability in the retina of diabetic rats. *Invest Ophthalmol Vis Sci*; 44:5410–5416.
12. **Barile GR, Pachydaki SI, Tari SR, et al. (2005)** : The RAGE axis in early diabetic retinopathy. *Invest Ophthalmol Vis Sci.*; 46(8):2916-24
13. **Behzadian MA, Wang XL, Windsor LJ, et al., (2001):** TGF- β increases retinal endothelial cell permeability by increasing MMP-9: possible role of glial cells in endothelial barrier function. *Invest Ophthalmol Vis Sci* ;42:853–859.

14. **Bill A ., (1975):** Blood circulation and fluid dynamics in the eye. *Physiol Rev* ; 55:383-417.
15. **Bhagat N, Grigorian R. A, Tutela A, Zarbin M. A., (2009):** Diabetic Macular Edema: Pathogenesis and Treatment. *Surv Ophthalmol*; 54:1-32.
16. **Blankenship GW., (1979):** Diabetic macular edema and argon laser photocoagulation: a prospective randomized study. *Ophthalmology*; 86:69–78
17. **Bolz M., Ritter M., Schneider M., et al., (2009):** A Systematic Correlation of Angiography and High-Resolution Optical Coherence Tomography in Diabetic Macular Edema *Ophthalmology* ;116:66–72
18. **Bonini-Filho MA, Jorge R, Barbosa JC, et al., (2005):** Intravitreal injection versus sub-Tenon’s infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial. *Invest Ophthalmol Vis Sci*;46:3845–3849.
19. **Boulton M & Dayhaw-Parker P., (2001):** The role of the retinal pigment epithelium: topographical variation and aging changes. *Eye* ; 15:384-389
20. **Brasil OF, Smith SD, Galor A, et al., (2007):** Predictive factors of short-term visual outcome after intravitreal triamcinolone acetonide injection for diabetic macular oedema: an optical coherence tomography study. *Br J Ophthalmol* ;91:761–765.

21. **Brown JC, Solomon SD, Bressler SB, et al., (2004):** Detection of diabetic foveal edema. Contact lens biomicroscopy compared with optical coherence tomography. Arch Ophthalmol ; 122:330 –335
22. **Browning D. J., Altaweel M. M., Bressler N. M., et al., (2008) :** Diabetic macular edema: What is focal and what is diffuse?. Am J Ophthalmol; 146:649 – 655.
23. **Browning DJ, & Fraser CM. (2005):** Regional patterns of sight-threatening diabetic macular edema. Am J Ophthalmol ;140: 117–124.
24. **Cai J. & Boulton M. (2002):** The pathogenesis of diabetic retinopathy: old concepts and new questions . Eye ;16:242–260
25. **Catier A, Tadayoni R, Paques M, et al., (2005):** Characterization of macular oedema from various aetiologies by optical coherence tomography. Am J Ophthalmol; 140: 200–206.
26. **Chan A., Duker J.S., Schuman J.S., Fujimoto J.G., (2004):** Stage 0 macular holes: observations by optical coherence tomography. Ophthalmology; 111: 2027–2032.
27. **Chen T.C., Cense B., Pierce M.C., et al., (2005):** Spectral domain optical coherence tomography: ultra-high speed, ultra-high resolution ophthalmic imaging. Arch. Ophthalmol., 123: 1715–1720.
28. **Chieh JJ, Roth DB, Liu M, et al. (2005):** Intravitreal triamcinolone acetate for diabetic macular edema. Retina ;25:828– 834

29. **Choma, M.A., Hsu K., Izatt J.A., (2005)** : Swept source optical coherence tomography using an all-fiber 1300-nm ring laser source. *J. Biomed. Opt.* 10,044009.
30. **Ciardella AP, Klancnik J, Schiff W, et al., (2004)**: Intravitreal triamcinolone for the treatment of refractory diabetic macular edema with hard exudates: an optical coherence tomography study. *Br J Ophthalmol* ; 88:1131–1136.
31. **Cook AR. (1901)** : Notes on the diseases met with in Uganda, central Africa. *J Trop Med.*, 4:175-178.
32. **Davidson MK, Russ PK, Glick GG, et al., (2000)**: Reduced expression of the adherens junction protein cadherin-5 in a diabetic retina. *Am J Ophthalmol* ;129: 267–269.
33. **Dejana E, (2004)**: Endothelial cell-cell junctions: happy together. *Nat Rev Mol Cell Biol* ;5:261–270.
34. **Drexler W, Sattmann H, Hermann B etal., (2003)** : Enhanced visualization of macular pathology with the use of ultrahigh resolution optical coherence tomography. *Arch Ophthalmol*; 121: 695–706
35. **Drexler W., (2004)** : Ultrahigh-resolution optical coherence tomography. *J Biomed Opt* ; 9: 47–74.

36. **Duker J. & Weiter JJ., (1991):** Ocular Circulation . in: Tasman W., Jaeger EA, ed. Duane's Foundation of Clinical Ophthalmology, New York: JB Lippincott; 1:1-34
37. **Eberli B, Riva CE, Feke GT., (1979):** Mean circulation time of fluorescein in retinal vascular segments. Arch Ophthalmol ; 97:145-148
38. **Diabetic Retinopathy Clinical Research Network, Scott IU., Edwards AR, et al., (2007):** A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology ;114:1860 – 1867.
39. **Elamin A, Omer MI, Zein K, Tuvemo T. (1992) ;** Epidemiology of childhood type I diabetes in Sudan, 1987-1990. Diabetes Care ; 15, 1556-1559.
40. **Elbagir MN, Eltom MA, Berne C. (1998) :** Classification of newly-onset IDDM and NIDDM in subjects aged 25-45 years in Sudan. J Intern Med; 244:443 450.
41. **Ernest JT., (1977):** The effect of systolic hypertension on rhesus monkey eyes after ocular sympathectomy. Am J Ophthalmol ; 84:341-344.
42. **Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al. (2000) :** Type 2 diabetes among North American children and adolescents: an

- epidemiologic review and a public health perspective. *J Pediatr.*, 136: 664-672.
43. **Famiglietti EV, Stopa EG, McGookin ED, et al. (2003)** : Immuno cytochemical localization of vascular endothelial growth factor in neurons and glial cells of human retina. *Brain Res.*, 969(1-2):195- 204
 44. **Feke GT, Tagawa H, Deupree DM, et al., (1989)**: Blood flow in the normal human retina. *Invest Ophthalmol Vis Sci.*, 30:58-65.
 45. **Feke GT, Zuckerman R, Green GJ, Weiter JJ., (1983)**: Responses of human retinal blood flow to light and dark. *Invest Ophthalmol Vis Sci.*, 24:136-141.
 46. **Fernandez-Patron C, Zouki C, Whittal R, et al., (2001)**: Matrix metalloproteinases regulate neutrophil-endothelial cell adhesion through generation of endothelin-1. *FASEB J*;15:2230–2240.
 47. **Fukai N, Eklund L, Marneros AG, et al., (2002)**: Lack of collagen XVIII/endostatin results in eye abnormalities. *EMBO J* ;21:1535–1544.
 48. **Gao BB, Clermont A, Rook S et al., (2007)**: Extracellular carbonic anhydrase mediates haemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. *Nat Med.*, 13: 181–188.
 49. **Gardner T.W., Antonetti D.A., Barber A.J., et al., (2002)**: Diabetic Retinopathy: more than meets the eye ; *Surv Ophthalmol* 47(Suppl 2):S253– S262.

50. **Gaucher D, Tadayoni R, Erginay A, et al., (2005):** Optical coherence tomography assessment of the vitreoretinal relationship in diabetic macular edema. *Am J Ophthalmol* ;139:807– 813.
51. **Giovannini A, Amato G, Mariotti C, Scassellati-Sforzolini B., (2000):** Optical coherence tomography findings in diabetic macular edema before and after vitrectomy. *Ophthalmic Surg Lasers* ;31:187–191.
52. **Goebel W & Kretzchmar-Gross T.(2002):** Retinal thickness in diabetic retinopathy: a study using optical coherence tomography (OCT). *Retina*; 22:759-67.
53. **Grant MB, May WS, Caballero S, et al., (2002):** Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. *Nat Med.*, 8:607–612.
54. **Guan K, Hudson C, Flanagan JG (2004):** Comparison of Heidelberg retina tomography II and the retinal thickness analyser in the assessment of diabetic macular oedema. *Invest Ophthalmol Vis Sci.*, 45: 610–616.
55. **Gürses-Özden R, Teng C, Vessani R, et al., (2004):** Macular and retinal nerve fiber layer thickness measurement reproducibility using optical coherence tomography (OCT-3). *J Glaucoma*;13:238-44.
56. **Gwatkin D, Guillot M, Heuveline P.(1999):** The burden of disease among the global poor. *Lancet*;354, 586-589.

57. **Hammes HP, Lin J, Bretzel RG, et al. (1998)** : Upregulation of the vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. *Diabetes* ;47:401—6
58. **Haritoglou C, Kook D, Neubauer A, et al., (2006)**: Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. *Retina* ;26:999 –1005
59. **Hassenstein A., Scholz F., & Richar, G., (2005)**: OCT in epiretinal gliosis. *Ophthalmologe* ;102:127–132.
60. **Hattori K, Heissig B, Wu Y, et al., (2002)**: Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1 stem cells from bone-marrow microenvironment. *Nat Med* ;8:841–849.
61. **Hayreh SS., (1962)**: The ophthalmic artery, Part III. Branches. *Br J Ophthalmol* ; 46:212-247.
62. **Herman W.H., Aubert R.E., Ali M.A., et al., (1997)** : Diabetes mellitus in Egypt: risk factors, prevalence and future burden. *EMHJ*; 3:144-148.
63. **Hikichi T, Fujio N, Akiba J, et al., (1997)** : Association between the short-term natural history of diabetic macular edema and the vitreomacular relationship in type II diabetes mellitus. *Ophthalmology* ;104(3):473—8.
64. **Hofman P, Blauwegers HG, Tolentino MJ, et al., (2000)**: VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in vivo is predominantly associated with pinocytotic vesicular transport and not

- with formation of fenestrations. Vascular endothelial growth factor-A. Curr Eye Res., 21:637–645.
65. **Imai M, Iijima H, Hanada N (2001):** Optical coherence tomography of tractional macular elevations in eyes with proliferative diabetic retinopathy. Am J Ophthalmol., 132:81- 4.
66. **Jaffe GJ & Caprioli J (2004) :** Optical coherence tomography to detect and manage retinal disease and glaucoma. Am J Ophthalmol 137: 156–169.
67. **Jiao S.L., Knighton R., Huang X.R., et al., (2005):** Simultaneous acquisition of sectional and fundus ophthalmic images with spectral-domain optical coherence tomography. Opt. Express., 13:444–452.
68. **Jin M, Kashiwagi K, Iizuka Y, et al. (2001) :** Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina ;21(1):28—31
69. **Jonas JB, Kreissig I, Sofker A, Degenring RF, (2003):** Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol ;121:57–61.
70. **Joussen A.M., Smyth N., Niessen C., (2007):** Pathophysiology of diabetic macular edema in : Diabetic retinopathy, edited by, Gabriele E. Lang, Basel (Switzerland), Karger, v. 39, ch. 1; pp1-12

71. **Joussen AM, Murata T, Tsujikawa A, et al., (2001):** Leukocyte-mediated endothelial cell injury and death in the diabetic retina. *Am J Pathol* ;158:147–152.
72. **Joussen AM, Poulaki V, Le ML, et al., (2004):** A central role for inflammation in the pathogenesis of diabetic retinopathy. *FASEB J* ;18:1450–1452.
73. **Joussen AM, Poulaki V, Mitsiades N, et al., (2003):** Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin induced diabetes. *FASEB J* ;17:76–78.
74. **Jumper JM, Embabi SN, Toth CA, et al. (2000) :** Electron immunocytochemical analysis of posterior hyaloid associated with diabetic macular edema. *Retina* ;20(1):63—8.
75. **Kang SW, Park CY, Ham DI. (2004):** The correlation between fluorescein angiographic and optical coherence tomographic features in clinically significant diabetic macular edema. *American Journal of Ophthalmology.* ;137(2): 313—22.
76. **Kakehashi A, Schepens CL, Trempe CL. (1994) :** Vitreomacular observations: I. Vitreomacular adhesion and hole in the premacular hyaloid. *Ophthalmology* ;101(9): 1515—1521.

77. **Kim BY, Smith SD, Kaiser PK, (2006):** Optical coherence tomographic patterns of diabetic macular edema. *Am J Ophthalmol* ;142:405– 412.
78. **Kimura T, Kiryu J, Nishiwaki H, et al. (2005) :** Efficacy of surgical removal of the internal limiting membrane in diabetic cystoid macular edema. *Retina* ;25(4):454—61
79. **King H, Aubert R, Herman W., (1998) :** Global burden of diabetes, 1995- 2025:prevalence, numerical estimates, and projections. *Diabetes Care* ;21:1414–1431.
80. **Kishi S. & Shimizu K. (1990) :** Posterior precortical vitreous pocket. *Arch Ophthalmol.*;108(7):979--82.
81. **Klein R, Klein Bek, Moss Se, Cruickshanks Kj., (1995):** The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long term incidence of macular edema. *Ophthalmology*. 1995;102:7—16
82. **Knudsen L. L. (2007) :** Identification of diabetic macular oedema using retinal thickness measurements *Acta Ophthalmol. Scand*. 85: 27–31
83. **Knudsen LL & Skriver K (2006):** A 3-dimensional evaluation of the macular region: comparing digitized and film-based media with a clinical evaluation. *Acta Ophthalmol Scand* 84: 296–300.
84. **Knudsen ST, Bek T, Logstrup poulsen p, et al., (2003):** effects of losartan on diabetic maculopathy in type 2 diabetic patients: a randomized, double-masked study. *Internal Medicine* ; 254: 147–158

85. **Ko T.H., Fujimoto J.G., Duker J.S., et al., (2004):** Comparison of ultrahigh- and standard-resolution optical coherence tomography for imaging macular hole pathology and repair. *Ophthalmology*; 111: 2033–2043.
86. **Ko T.H., Fujimoto J.G., Schuman J.S., et al., (2005) :** Comparison of ultrahigh- and standard-resolution optical coherence tomography for imaging macular pathology. *Ophthalmology*; 112; 1922.
87. **Kondo T, Hafezi-Moghadam A, Thomas K, et al., (2004):** Mice lacking insulin or insulin-like growth factor 1 receptors in vascular endothelial cells maintain normal blood-brain barrier. *Biochem Biophys Res Commun* ;317:315–320.
88. **kozak I , Morrison V. L., Clark T. M., et al., (2008) :** Discrepancy between fluorescein angiography and optical coherence tomography in detection of macular disease. *Retina*; 28:538–544.
89. **Krepler K, Wagner J, Sacu S, Wedrich A., (2005):** The effect if intravitreal triamcinolone on diabetic macular oedema. *Graefes Arch Clin Exp Ophthalmol* ;243:478 – 481
90. **Kumar A, Sinha S, Azad R, et al., (2007):** Comparative evaluation of vitrectomy and dye-enhanced ILM peel with grid laser in diffuse diabetic macular edema. *Graefes Arch Clin Exp Ophthalmol* ;245:360 –368.

91. **Laties AM. & Jacobwitz D., (1966):** A comparative study of the autonomic innervation of the eye in monkey, cat and rabbit. *Anat Rec* ; 156:383-396.
92. **Leach L, Gray C, Staton S, et al., (2004):** Vascular endothelial cadherin and β -catenin in human fetoplacental vessels of pregnancies complicated by type 1 diabetes: associations with angiogenesis and perturbed barrier function. *Diabetologia* ;47:695–709.
93. **Libby RT, Champliand MF, Claudepierre T, et al., (2000):** Laminin expression in adult and developing retinae: evidence of two novel CNS laminins. *J Neurosci* ;20:6517–6528.
94. **Lipman TH. (1993) :** The epidemiology of type I diabetes in children 0-14 yr of age in Philadelphia. *Diabetes Care* ; 16, 922-925.
95. **Lipman TH, Jawad AF, Murphy K, et al. (2001) :** Incidence of type 1 diabetes in Philadelphia is higher in Black than white children from 1995-2000: Epidemic or misclassification?.*Diabetes* ; 50, A39.
96. **Lonai P, (2003):** Epithelial mesenchymal interactions, the ECM and limb development. *J Anat* ;202: 43–50.
97. **Lovestam-Adrian M & Agardh E., (2000):** Photocoagulation of diabetic macular oedema complications and visual outcome. *Acta Ophthalmol Scand* ;78:667– 671.

98. **Malek R, Belateche F, Laouamri S, et al. (2001)** : Prevalence of type 2 diabetes mellitus and glucose intolerance in the Setif area (Algeria). *Diabetes Metab*; 27, 164-171.
99. **Malik M., Bakir A, Saab BA, King H., (2005):** Glucose intolerance and associated factors in the multi-ethnic population of the United Arab Emirates: results of a national survey. *Diabetes Res Clin Pract.*, 69(2):188–95.
100. **Marmor MF & Martin LJ., (1978):** 100 Years of the visual cycle. *Surv Ophthalmol* ; 22:279-285
101. **Marmor MF., (1991):** Clinical electrophysiology of the retinal pigment epithelium. *Doc Ophthalmol* ; 76:301-313.
102. **Massin P, Duguid G, Erginay A, et al., (2003):** Optical coherence tomography for evaluating diabetic macular oedema before and after vitrectomy. *Am J Ophthalmol* 135: 169–177.
103. **Massin P, Girach A, Erginay A, Gaudric A (2006)** : Optical coherence tomography: a key to the future management of patients with diabetic macular oedema. *Acta Ophthalmol. Scand.* : 84: 466–474
104. **Mathews V, Hanson PT, Ford E, et al., (2004):** Recruitment of bone marrow derived endothelial cells to sites of pancreatic -cell injury. *Diabetes* ;53:91–98.

105. **Matter K & Balda MS, (2003):** Signalling to and from tight junctions. Nat Rev Mol Cell Biol ;4: 225–236.
106. **Mbanya JC, Cruickshank JK, Forrester T, et al. (1999) :** Standardized comparison of glucose intolerance in west African-origin populations of rural and urban Cameroon, Jamaica, and Caribbean migrants to Britain. Diabetes Care. ; 22, 434-440
107. **McDonnell JM., (1989):** Ocular embryology and anatomy. In Ryan SJ, Ogden TE (eds): Retina, Vol 1. St. Louis: CV Mosby, 1989:11-15
108. **McLarty DG, Pollitt C, Swai ABM.(1990) :** Diabetes in Africa. Diab Med ; 7:670–684.
109. **Michelson G. & Jarazny J., (1997):** Relationship between ocular pulse pressures and retinal vessel velocities. Ophthalmology 1997; 104:664-671.
110. **Mirza R. G., Johnson M. W., Jampol L. M., (2007):** Optical Coherence Tomography use in evaluation of the vitreoretinal interface: A review. Surv Ophthalmol., 52:397- 421.
111. **Mosley WH, Bobadilla JL., Jamison DT, (1993) :** The health transition: Implications for health policy in developing countries. In: Disease control priorities in developing countries, edited by Dean T. Jamison et al., New York/Oxford, England, Oxford University Press; 673-99.

112. **Motala A.A., Omar MA, Pirie FJ (2003)** : Diabetes in Africa. Epidemiology of type 1 and type 2 diabetes in Africa. J Cardiovasc Risk.;10(2):77-83
113. **Neubauer A.S., Chryssafis C., Priglinger S.G., et al., (2007):** Topography of diabetic macular oedema compared with fluorescein angiography. Acta Ophthalmol. Scand., 85: 32–39.
114. **Nguyen QD, Shah SM, Van Anden E, et al. (2004)** : Supplemental oxygen improves diabetic macular edema: a pilot study. Invest Ophthalmol Vis Sci.;45(2):617—24
115. **Nussbaum JJ, Pruett RC, Delori FC., (1981):** Historic perspectives ,Macular yellow pigment: The first 200 years. Retina 1:296.
116. **Omar MA, Seedat MA, Dyer RB, et al. (1994)** : South African Indians show a high prevalence of NIDDM and bimodality in plasma glucose distribution patterns. Diabetes Care ; 17, 70-73.
117. **Otani A, Kinder K, Ewalt K, et al., (2002):** Bone marrow-derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis. Nat Med ;8: 1004–1010.
118. **Otani T. & Kishi S.,(2007):** Correlation between Optical Coherence Tomography and Fluorescein Angiography Findings in Diabetic Macular Edema Ophthalmology ;114:104–107

119. **Oussama K. M.N, (2006):** Diabetes in the Eastern Mediterranean Region . in Guidelines for the prevention, management and care of diabetes mellitus, WHO regional office for the eastern mediterranean. (EMRO Technical Publications Series ;32:9-12)
120. **Özdek S.C., Erdinç M.A., Gürelik G., et al., (2005):** Optical Coherence Tomographic Assessment of Diabetic Macular Edema: Comparison with Fluorescein Angiographic and Clinical Findings; Ophthalmologica ;219:86–92
121. **Panozzo G, Gusson E, Parolini B, et al., (2003):** Role of OCT in the diagnosis and follow up of diabetic macular edema. Semin Ophthalmol 18:74—81.
122. **Parver LM, Auker C, Carpenter DO., (1980):** Choroidal blood flow as a heat dissipating mechanism in the macula. Am J Ophthalmol ; 84:641-646.
123. **Papoz L, Delcourt C, Ponton-Sanchez A, et al. (1998) :** Clinical classification of diabetes in tropical west Africa. Diabetes Res Clin Pract ; 39, 219-227.
124. **Piecha D, Hartmann K, Kobbe B, et al., (2002):** Expression of matriline-2 in human skin. J Invest Dermatol ;119:38–43.

125. **Polito A, Del Borrello M, Isola M, et al., (2005):** Repeatability and reproducibility of fast macular thickness mapping with stratus optical coherence tomography. Arch Ophthalmol;123:1330-1337
126. **Pons, M.E., Garcia-Valenzuela, E.,(2005) :** Redefining the limit of the outer retina in optical coherence tomography scans. Ophthalmology; 112: 1079–1085.
127. **Qaum T, Xu Q, Jousen AM, Qin W, Clemens ME, Yancopoulos GD & Adamis AP, (2001):** Early diabetic blood-retinal barrier breakdown is VEGF-dependent. Invest Ophthalmol Vis Sci ;42: 2408–2413.
128. **Rafii S, Lyden D, Benezra R, et al., (2002):** Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy. Nat Rev Cancer ;2:826–835.
129. **Rivellese M, George A, Sulkes D, et al., (2000):** Optical coherence tomography after laser photocoagulation for clinically significant macular edema. Ophthalmic Surg Lasers; 31: 192–7.
130. **Rochon-Duvigneaud A., (1907):** Recherches sur la fovea de la retine humaine et particulierement sur le bouquet des cones centraux. Arch Anat Microsc ; 9:315-342. Quoted from **Schubert H.D. (2004):** Structure and Function of the Neural Retina. In: Yanoff Ophthalmology, 2nd ed., edited by Jay S. Duker., Philadelphia, mosby. ch99.

131. **Roh S. & Weiter J., (2004)** : Retinal and Choroidal Circulation. In; Yanoff Ophthalmology, 2nd ed., edited by; Jay S. Duker., St. Louis, mosby., ch.101.
132. **Romero-Aroca P, Fernández-Balart J, Baget-Bernaldiz M, et al., (2008)** : Changes in the diabetic retinopathy epidemiology after 14 years in a population of Type 1 and 2 diabetic patients after the new diabetes mellitus diagnosis criteria and a more strict control of the patients., J Diabetes Complications; 23(4):229-38
133. **Rosenblatt BJ, Shah GK, Sharma S, Bakal J. (2005)** : Pars plana vitrectomy with internal limiting membranectomy for refractory diabetic macular edema without a taut posterior hyaloid. Graefes Arch Clin Exp Ophthalmol. ;243(1): 20—5.
134. **Sadda SR, Tan O, Walsh AC, et al., (2006)**: Automated detection of clinically significant macular edema by grid scanning optical coherence tomography. Ophthalmology ;113:1187.el– e12.
135. **Salzmann J, Limb GA, Khaw PT, et al., (2000)**: Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol ;84:1091–1096.
136. **Sander B, Larsen M, Engler C, et al., (2002)**: Diabetic macular oedema: a comparison of vitreous fluorometry, angiography, and retinopathy. Br J Ophthalmol ;86:316 –320.

137. **Sander B, Larsen M, Moldow B, Lund-Andersen H, (2001):** Diabetic macular edema: passive and active transport of fluorescein through the blood-retina barrier. *Invest Ophthalmol Vis Sci* ;42:433–438.
138. **Saraiva FP, Costa PG, Inomata DL, et al., (2007):** Consistency of ocular coherence tomography fast macular thickness mapping in diabetic diffuse macular edema. *Clinics*;62(6):721-4.
139. **Schmidt-Erfurth U., Leitgeb R.A., Michels S., et al., (2005):** Three dimensional ultrahigh-resolution optical coherence tomography of macular diseases. *Invest. Ophthalmol. Vis. Sci.* 46: 3393–3402.
140. **Schubert H.D. (2004):** Structure and Function of the Neural Retina. In, Yanoff: *Ophthalmology*, 2nd ed., edited by Jay S. Duker., Philadelphia, mosby. Ch. 99.
141. **Schuman, J.S., Puliafito, C.A., Fujimoto, J.G., (2004):** Optical coherence tomography of ocular diseases. 2nd ed. SLACK Inc., Thorofare.
142. **Sebag J. (1992) :** Anatomy and pathology of the vitreo-retinal interface. *Eye*.;6 (Pt 6):541—52.
143. **Shimizu K & Kazuyoshi U., (1978):** Structure of ocular vessels, New York, Igaku-Shoin. Quoted from **Roh S., Weiter J., (2004) :** Retinal and Choroidal Circulation. In; Yanoff: *Ophthalmology*, 2nd ed., edited by; Jay S. Duker., St. Louis, mosby., ch.101

144. **Sobngwi E., Mauvais-jarvis F., vexiau P., et al., (2001) :** diabetes in Africans part 1: epidemiology and clinical specificities. *diabetes metab.*, 27: 628-634
145. **Soliman W, Sander B, Jørgensen TM (2007):** Enhanced optical coherence patterns of diabetic macular oedema and their correlation to the pathophysiology. *Acta Ophthalmol Scand.*, 85(6):613-617
146. **Soliman W., Sander B., Hasler P.W., Larsen M. (2008):** Correlation between intraretinal changes in diabetic macular oedema seen in fluorescein angiography and optical coherence tomography; *Acta Ophthalmol.*, 86: 34–39.
147. **Stefansson E. (2001) :** The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. *Acta Ophthalmol Scand.* ;79(5): 435—40.
148. **Strom C, Sander B, Larsen N, et al., (2002)** Diabetic macular edema assessed with optical coherence tomography and stereo fundus photography. *Invest Ophthalmol Vis Sci* ; 43: 241–5.
149. **Susanna S. Park (2007) :** The anatomy and cell biology of the retina. in : *Duane's foundations in Ophthalmology*, edited by Tasman, William; Jaeger, Edward A., Philadelphia ,mosby., v.1, ch. 19.
150. **Talwar D, Sharma N, Pai A, et al., (2001):** Contrast sensitivity following focal laser photocoagulation in clinically significant macular

- oedema due to diabetic retinopathy. Clin and Experiment Ophthalmol ;29:17–21.
151. **Thomas D, Bunce C, Moorman C, et al., (2005):** Frequency and associations of a taut thickened posterior hyaloid, partial vitreomacular separation, and subretinal fluid in patients with diabetic macular edema. Retina 25:883—8.
152. **Tranos P.G., Wickremasinghe S.S., Stangos N.T., et al., (2004):** Macular Edema , major review. Surv Ophthalmol., 49:470–490,
153. **Uchino E, Uemura A, Ohba N (2001):** Initial stages of posterior vitreous detachment in healthy eyes of older persons evaluated by optical coherence tomography. Arch Ophthalmol 119: 1475–1479.
154. **Unterhuber A., Povazay B., Hermann B., et al., (2003):** Compact, low-cost Ti:Al₂O₃ laser for in vivo ultrahigh-resolution optical coherence tomography. Opt. Lett. 28: 905–907.
155. **Van Velthoven M.E., Faber D.J., Frank D., et al., (2007) :** Recent developments in optical coherence tomography for imaging the retina Progress in Retinal and Eye Research; 26: 57–77.
156. **Van Velthoven, M.E., de Smet MD., Schlingemann R.O., et al., (2006a):** Added value of OCT in evaluating the presence of leakage in patients with age-related macular degeneration treated with PDT.. Graefes Arch. Clin. Exp. Ophthalmol. 244(9):1119-23.

157. **Van Velthoven M.E., Verbraak F.D., Yannuzzi L.A., et al., (2006b):**
Imaging the retina by enface optical coherence tomography. *Retina* 26,
129–136.
158. **Van Velthoven M.E.J., Van de Linden M.H., De Smet M.D., et al.,
(2006c):** Influence of cataract on optical coherence tomography image
quality and retinal thickness. *Br. J. Ophthalmol.* 90, 1259–1262.
159. **Wagenblast P.C., Ko T.H., Fujimoto J.G., et al., (2004):** Ultrahigh-
resolution optical coherence tomography with a diode-pumped broadband
Cr³⁺: LiCAF laser. *Opt. Express.*, 12: 3257–3263.
160. **Walsh K & Sata M, (1999):** Is extravasation a Fas-regulated process?
Mol Med Today ;5:61–67.
161. **Weiter JJ. & Ernest JT.,(1974):** Anatomy of the choroidal vasculature.
Am J Ophthalmol ; 78:583-590.
162. **Weiter JJ, Schachar RA, Ernest JT., (1973a):** Control of intraocular
blood flow, (I). Intraocular pressure. *Invest Ophthalmol* ; 12:327-331.
163. **Weiter JJ, Schachar RA, Ernest JT., (1973b) :** Control of intraocular
blood flow. (II) Effects of sympathetic tone. *Invest Ophthalmol* ; 12:332-
334.
164. **Weiter JJ. & Zuckerman R., (1980):** The influence of the
photoreceptor-RPE complex on the inner retina: an explanation for the
beneficial effects of photocoagulation. *Ophthalmology* ; 87:1133-1139.

165. **Witmer AN, Vrensen GF, VanNoorden CJ, Schlingemann RO., (2003) :** Vascular endothelial growth factors and angiogenesis in eye disease. *Prog Retin Eye Res.* ;22(1):1—29
166. **Wojtkowski M., Srinivasan V., Fujimoto J.G., et al., (2005):** Three-dimensional retinal imaging with high-speed ultrahigh-resolution optical coherence tomography. *Ophthalmology.*, 112: 1734–1746.
167. **Wolburg H & Lippoldt A, (2002):** Tight junctions of the blood-brain barrier: development, composition and regulation. *Vascul Pharmacol* ;38:323–337.
168. **Yang CS, Cheng CY, Lee FL, et al., (2001):** Quantitative assessment of retinal thickness in diabetic patients with and without clinically significant macular edema using optical coherence tomography. *Acta Ophthalmol Scand*; 79:266-70.
169. **Yanyali A, Horozoglu F, Celik E, Nohutcu AF (2007):** Long-term outcomes of pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. *Retina* ; 27:557–566.
170. **Zein WM, Nouredin BN, Jurdi FA, et al., (2006):** Panretinal photocoagulation and intravitreal triamcinolone acetonide for the management of proliferative diabetic retinopathy with macular edema. *Retina* ;26:137–142.